A detailed history of Asset Management Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Asset Management Corp holds 7,156 shares of BMY stock, worth $399,090. This represents 0.34% of its overall portfolio holdings.

Number of Shares
7,156
Previous 7,133 0.32%
Holding current value
$399,090
Previous $513,000 3.51%
% of portfolio
0.34%
Previous 0.41%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023

BUY
$65.71 - $74.53 $1,511 - $1,714
23 Added 0.32%
7,156 $495,000
Q4 2022

Jan 24, 2023

SELL
$68.48 - $81.09 $84,161 - $99,659
-1,229 Reduced 14.7%
7,133 $0
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $2 - $1,383
18 Added 0.22%
8,362 $594,000
Q2 2022

Aug 01, 2022

BUY
$72.62 - $79.98 $1,307 - $1,439
18 Added 0.22%
8,344 $642,000
Q1 2022

May 03, 2022

BUY
$61.48 - $73.72 $42,605 - $51,087
693 Added 9.08%
8,326 $608,000
Q4 2021

Jan 25, 2022

SELL
$53.63 - $62.52 $8,151 - $9,503
-152 Reduced 1.95%
7,633 $476,000
Q3 2021

Oct 13, 2021

BUY
$59.17 - $69.31 $1,124 - $1,316
19 Added 0.24%
7,785 $461,000
Q2 2021

Aug 06, 2021

SELL
$61.91 - $67.42 $86,178 - $93,848
-1,392 Reduced 15.2%
7,766 $519,000
Q1 2021

May 04, 2021

SELL
$59.34 - $66.74 $28,245 - $31,768
-476 Reduced 4.94%
9,158 $578,000
Q4 2020

Jan 29, 2021

BUY
$57.74 - $65.43 $1,328 - $1,504
23 Added 0.24%
9,634 $641,000
Q3 2020

Oct 26, 2020

BUY
$57.43 - $63.64 $1,320 - $1,463
23 Added 0.24%
9,611 $579,000
Q2 2020

Jul 21, 2020

SELL
$54.82 - $64.09 $59,698 - $69,794
-1,089 Reduced 10.2%
9,588 $564,000
Q1 2020

Apr 14, 2020

BUY
$46.4 - $67.43 $1,299 - $1,888
28 Added 0.26%
10,677 $595,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $524,037 - $683,559
10,649 New
10,649 $684,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Asset Management Corp Portfolio

Follow Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Asset Management Corp with notifications on news.